Stage 4 cancer, often referred to as metastatic cancer or advanced stage cancer, represents a diagnosis where primary tumour cells have detached from their original anatomical site and migrated to distant organs, tissues, or lymph nodes via the circulatory or lymphatic systems.
As a medical practitioner specialising in oncology, I frequently address the anxiety surrounding this diagnosis. Whilst a stage 4 diagnosis historically carried a limited prognosis, modern systemic therapies, molecular profiling, and precision medicine have redefined how we manage advanced malignancies, transforming many into chronic, controllable conditions.
What Causes Stage 4 Cancer to Develop?
Stage 4 cancer does not occur overnight. It is the result of a multi-step biological process known as the metastatic cascade:
- Local Invasion: Cancer cells lose cell-to-cell adhesion (often through epithelial-mesenchymal transition) and invade surrounding stroma.
- Intravasation: Malignant cells breach the walls of nearby blood vessels or lymphatic channels.
- Circulation and Survival: Cells travel through the bloodstream or lymphatics while evading immune surveillance.
- Extravasation: The circulating cells exit the microvasculature into a secondary, distant organ tissue—such as the liver, lungs, bones, or brain.
- Colonisation: The cells adapt to the new microenvironment, stimulate angiogenesis (new blood vessel formation), and establish secondary tumours.
Common secondary sites depend heavily on the primary organ due to vascular anatomy (the “seed and soil” hypothesis). For example, colorectal cancers frequently metastasise to the liver via the portal vein system, whilst lung and breast cancers commonly spread to the brain and bone structures.
Modern Treatment Modalities for Stage 4 Cancer
Treatment for advanced stage cancer shifts primary goals from absolute eradication to long-term disease control, survival extension, and symptom management. Systemic treatments form the backbone of therapy because localised modalities (like surgery or localized radiotherapy) cannot address micro-metastases throughout the body.
Systemic Therapies
- Targeted Therapy: Precision medications designed to block specific molecular targets or genetic driver mutations (e.g., EGFR or ALK alterations in non-small cell lung cancer, HER2-positive breast cancers).
- Immunotherapy: Immune checkpoint inhibitors (such as PD-1/PD-L1 and CTLA-4 blockers) reactivate the host immune system to recognise and destroy metastatic cancer cells.
- Chemotherapy: Cytotoxic agents administered systemically to disrupt rapidly dividing cells across all body systems.
- Hormone Therapy: Used in hormone-receptor-positive breast and prostate cancers to block the signals that promote tumour growth.
Localised Interventions in Advanced Disease
In select cases, localised treatments remain essential:
- Oligometastatic Surgery/SBRT: When metastasised lesions are limited (usually 1 to 5 spots), Stereotactic Body Radiotherapy (SBRT) or surgical resection can prolong disease-free survival.
- Palliative Care and Radiotherapy: Used to alleviate symptoms such as bone pain, spinal cord compression, or airway obstruction, thereby preserving quality of life.
Survival Rates and Prognostic Factors
Survival outcomes in stage 4 cancer vary significantly depending on the primary tumour origin, biomarker expression, and patient performance status. Statistics are formally reported using the 5-year relative survival rate, which compares individuals diagnosed with a specific cancer stage to the general population.
Prostate cancer exhibits a 5-year relative survival rate of approximately 37% at Stage 4. Key prognostic factors include hormone sensitivity, prostate-specific antigen (PSA) response rates, and whether metastases are confined to the bones or extend to visceral organs.
Metastatic breast cancer carries an estimated 5-year relative survival rate of roughly 32%. Outcomes heavily depend on receptor status—such as HR-positive, HER2-positive, or triple-negative profiles—as well as overall tumour burden.
Advanced stage melanoma of the skin demonstrates a 5-year relative survival rate of around 35%. Prognostic determinants are strongly driven by BRAF mutation status and the patient’s individual response to dual checkpoint inhibitor immunotherapy.
Colorectal cancer diagnosed at Stage 4 shows an estimated 5-year relative survival rate of approximately 16%. Survival relies on the resectability of secondary liver or lung lesions, alongside molecular markers like RAS, BRAF, and microsatellite instability (MSI) status.
Non-small cell lung cancer (NSCLC) at Stage 4 carries a 5-year relative survival rate of about 9%. However, survival is substantially influenced by actionable driver mutations (such as EGFR, ALK, or ROS1) and high PD-L1 expression levels, which allow for durable responses to targeted therapy and immunotherapy.
It is crucial to note that historical statistics reflect patient outcomes diagnosed years prior. The rapid integration of targeted therapy and immune checkpoint inhibitors has significantly improved real-world survival for many stage 4 patients, far exceeding historical cohort averages.
Palliative Care: Enhancing Quality of Life
Palliative care is a specialised medical approach focused on providing relief from symptoms, pain, and stress associated with advanced illness. Incorporating palliative care early alongside active oncological treatment improves patient outcomes, symptom management, and psychological well-being throughout the stage 4 treatment journey.
